SOPHiA GENETICS (SOPH) Stock Price, News & Analysis

Company Overview

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

Key Stats

• Today's Range: $3.70 to $4.35
• 50-Day Range: $2.89 to $4.33
• 52-Week Range: $2.70 to $7.37
• Volume: 119,420 shs
• Average Volume: 48,096 shs
• Market Capitalization: $274.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.40
• Consensus Rating: Moderate Buy

SOPHiA GENETICS Stock Analysis - MarketRank™

SOPHiA GENETICS scored higher than 55% of companies evaluated by MarketBeat, and ranked 480th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

SOPHiA GENETICS has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

SOPHiA GENETICS has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for SOPHiA GENETICS are expected to grow in the coming year, from ($0.96) to ($0.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of SOPHiA GENETICS is -3.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of SOPHiA GENETICS is -3.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.06% of the float of SOPHiA GENETICS has been sold short.

Short Interest Ratio / Days to Cover

SOPHiA GENETICS has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SOPHiA GENETICS has recently decreased by 15.14%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SOPHiA GENETICS does not currently pay a dividend.

Dividend Growth

SOPHiA GENETICS does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.06% of the float of SOPHiA GENETICS has been sold short.

Short Interest Ratio / Days to Cover

SOPHiA GENETICS has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SOPHiA GENETICS has recently decreased by 15.14%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.10

News Sentiment

SOPHiA GENETICS has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for SOPHiA GENETICS this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for SOPH on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SOPHiA GENETICS insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.88% of the stock of SOPHiA GENETICS is held by insiders.

Percentage Held by Institutions

Only 31.59% of the stock of SOPHiA GENETICS is held by institutions.

SOPH Stock Analysis - Frequently Asked Questions

How have SOPH shares performed this year?

SOPHiA GENETICS's stock was trading at $3.07 at the beginning of the year. Since then, SOPH shares have increased by 36.8% and is now trading at $4.20.
View the best growth stocks for 2025 here.

How were SOPHiA GENETICS's earnings last quarter?

SOPHiA GENETICS SA (NASDAQ:SOPH) released its earnings results on Tuesday, November, 5th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.04. The business earned $15.85 million during the quarter, compared to the consensus estimate of $15.90 million. SOPHiA GENETICS had a negative net margin of 110.71% and a negative trailing twelve-month return on equity of 55.06%.

When did SOPHiA GENETICS IPO?

SOPHiA GENETICS (SOPH) raised $234 million in an initial public offering on Friday, July 23rd 2021. The company issued 13,000,000 shares at $17.00-$19.00 per share.

Who are SOPHiA GENETICS's major shareholders?

Top institutional shareholders of SOPHiA GENETICS include Green Alpha Advisors LLC (0.07%) and Silverberg Bernstein Capital Management LLC (0.03%).

How do I buy shares of SOPHiA GENETICS?

Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SOPHiA GENETICS own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SOPHiA GENETICS investors own include Occidental Petroleum (OXY), PayPal (PYPL), Chesapeake Energy (CHK), Cheniere Energy (LNG), Rocket Pharmaceuticals (RCKT), AbCellera Biologics (ABCL) and Farmers & Merchants Bancorp (FMAO).

Company Calendar

• Last Earnings: 11/05/2024
• Today: 1/25/2025
• Next Earnings (Estimated): 3/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SOPH
• CUSIP: N/A
• CIK: 1840706
• Web: www.sophiagenetics.com
• Phone: 41-21-694-1060
• Fax: N/A
• Employees: 520
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.40
• High Stock Price Target: $11.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +76.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-78,980,000.00
• Net Margins: -110.71%
• Pretax Margin: -109.76%
• Return on Equity: -55.06%
• Return on Assets: -38.33%

Debt

• Debt-to-Equity Ratio: 0.12
• Current Ratio: 3.80
• Quick Ratio: 3.59

Sales & Book Value

• Annual Sales: $62.37 million
• Price / Sales: 4.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 65,380,000
• Free Float: 62,185,000
• Market Cap: $274.60 million
• Optionable: Not Optionable
• Beta: 1.00